*ST Longjin (002750.SZ) announced a performance forecast for the first half of 2024. The net income attributed to shareholders of the listed company was a loss of 3.6 million yuan to 4.9 million yuan, compared to a loss of 15.7777 million yuan in the same period last year; the net income after deducting non-recurring gains and losses was a loss of 9.7 million yuan to 13.15 million yuan, compared to a loss of 19.4725 million yuan in the same period last year; and the basic earnings per share was a loss of 0.0090 yuan/share to 0.0122 yuan/share.
Due to policy factors such as the restriction of medical insurance payments and hospital prescriptions, and the company's injection of chrysanthemum extract for lowering prices by 67% to participate in the inter-provincial alliance of Chinese patent medicines for centralized and quantity-based procurement, non-procurement provinces gradually implemented the procurement price linkage policy, resulting in a decrease in the company's revenue for this period.
During the reporting period, the company implemented cost reduction measures to improve the utilization rate of production capacity, reduce production costs, fine-grained management of sales and management expenses, and at the same time, R&D projects gradually entered the capitalization stage, R&D expenses decreased, and the company received compensation from the committed party for performance, resulting in a decrease in the loss compared to the same period last year.